Neurocrine Biosciences Inc (NBIX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $16.94B
Last updated: Nov 17, 2026 at 11:05 AM ET
Neurocrine Biosciences Inc (NBIX) Earnings: Report Dates and Results
Neurocrine Biosciences (NBIX) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Neurocrine Biosciences reported EPS of $2.78, above the $1.95 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NBIX has an expected report date of Feb 9, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 7.4% above the $1.88 reported for the quarter ended Dec 31, 2025.
NBIX Earnings Call
The latest NBIX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, NBIX beat 17, missed 22 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.12B, up 40.9% from $794.90M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $2.78 | $1.95 | N/A | +42.56% | Beat | +28.1% | 17 | 1 up, 1 down | Nov 2, 2026 | $1.12B |
| Jun 30, 2026 | $2.36 | $1.88 | -$1.90 - $3.16 | +25.53% | Beat | +43.0% | 15 | 2 up, 1 down | Jul 30, 2026 | $959.00M |
| Mar 31, 2026 | $1.94 | $1.70 | $1.42 - $2.17 | +14.12% | Beat | +177.1% | 13 | 2 up, 5 down | May 5, 2026 | $814.50M |
| Dec 31, 2025 | $1.88 | $2.30 | $2.04 - $2.81 | -18.26% | Miss | +11.2% | 15 | 1 up, 10 down | Feb 11, 2026 | $805.50M |
| Sep 30, 2025 | $2.17 | $2.07 | $1.78 - $2.54 | +4.83% | Beat | +19.9% | 16 | 2 up, 3 down | Oct 28, 2025 | $794.90M |
| Jun 30, 2025 | $1.65 | $1.50 | $1.34 - $1.80 | +10.00% | Beat | +1.2% | 15 | 1 up, 3 down | Jul 30, 2025 | $687.50M |
| Mar 31, 2025 | $0.70 | $1.09 | $0.15 - $1.65 | -35.78% | Miss | -41.7% | 14 | 1 up, 10 down | May 5, 2025 | $572.60M |
| Dec 31, 2024 | $1.69 | $1.93 | $0.50 - $2.35 | -12.44% | Miss | +9.7% | 13 | 3 up, 2 down | Feb 6, 2025 | $627.70M |
| Sep 30, 2024 | $1.81 | $1.82 | $1.26 - $2.12 | -0.55% | Miss | +17.5% | 19 | 6 up, 0 down | Oct 30, 2024 | $622.10M |
| Jun 30, 2024 | $1.63 | $1.53 | $0.27 - $1.71 | +6.54% | Beat | +30.4% | 17 | 3 up, 0 down | Aug 1, 2024 | $590.20M |
| Mar 31, 2024 | $1.20 | $1.29 | $0.18 - $1.77 | -6.98% | Miss | N/A | 18 | 6 up, 4 down | May 1, 2024 | $515.30M |
| Dec 31, 2023 | $1.54 | $1.51 | N/A | +1.99% | Beat | +24.2% | 19 | 6 up, 1 down | Feb 7, 2024 | $515.20M |
| Sep 30, 2023 | $1.54 | $1.33 | $0.35 - $1.35 | +15.79% | Beat | +42.6% | 18 | 6 up, 0 down | Oct 31, 2023 | $498.80M |
| Jun 30, 2023 | $1.25 | $1.12 | N/A | +11.61% | Beat | +48.8% | 17 | 10 up, 0 down | Aug 1, 2023 | $452.70M |
| Mar 31, 2023 | -$0.51 | $0.74 | -$0.85 - $1.11 | -168.92% | Miss | -270.0% | 19 | 1 up, 0 down | May 3, 2023 | $420.40M |
| Dec 31, 2022 | $1.24 | $1.44 | $0.73 - $2.45 | -13.89% | Miss | +3000.0% | 17 | 4 up, 1 down | Feb 6, 2023 | $412.00M |
| Sep 30, 2022 | $1.08 | $1.12 | $0.21 - $1.16 | -3.57% | Miss | +68.8% | 18 | 7 up, 0 down | Nov 1, 2022 | $387.90M |
| Jun 30, 2022 | $0.84 | $0.89 | N/A | -5.62% | Miss | +33.3% | 15 | 4 up, 0 down | Aug 4, 2022 | $378.20M |
| Mar 31, 2022 | $0.30 | $0.59 | $0.19 - $0.70 | -49.15% | Miss | -38.8% | 19 | 4 up, 0 down | May 4, 2022 | $310.60M |
| Dec 31, 2021 | $0.04 | $0.88 | -$0.83 - $1.06 | -95.45% | Miss | -95.6% | 19 | 2 up, 1 down | Feb 11, 2022 | $312.00M |
| Sep 30, 2021 | $0.64 | $0.80 | $0.06 - $1.06 | -20.00% | Miss | -34.0% | 18 | N/A | Nov 1, 2021 | $296.00M |
| Jun 30, 2021 | $0.63 | $0.76 | N/A | -17.11% | Miss | -55.6% | 18 | N/A | Aug 3, 2021 | $288.90M |
| Mar 31, 2021 | $0.49 | $0.72 | -$0.03 - $0.81 | -31.94% | Miss | -40.2% | 19 | N/A | May 5, 2021 | $236.60M |
| Dec 31, 2020 | $0.91 | $0.90 | -$0.59 - $0.93 | +1.11% | Beat | +160.0% | 20 | N/A | Feb 4, 2021 | $247.90M |
| Sep 30, 2020 | $0.97 | $1.25 | -$0.65 - $1.43 | -22.40% | Miss | +73.2% | 20 | N/A | Nov 9, 2020 | $258.50M |
| Jun 30, 2020 | $1.42 | $1.02 | $0.17 - $1.38 | +39.22% | Beat | +163.0% | 19 | N/A | Aug 3, 2020 | $302.40M |
| Mar 31, 2020 | $0.82 | $0.64 | $0.05 - $0.87 | +28.13% | Beat | N/A | 22 | N/A | May 6, 2020 | $237.10M |
| Dec 31, 2019 | $0.35 | $0.75 | $0.23 - $0.95 | -53.33% | Miss | +84.2% | 18 | N/A | Feb 4, 2020 | $244.10M |
| Sep 30, 2019 | $0.56 | $0.64 | $0.23 - $0.84 | -12.50% | Miss | +7.7% | 19 | N/A | Nov 4, 2019 | $222.10M |
| Jun 30, 2019 | $0.54 | $0.25 | -$1.30 - $0.64 | +116.00% | Beat | N/A | 17 | N/A | Jul 29, 2019 | $183.50M |
| Mar 31, 2019 | -$1.12 | -$0.89 | -$1.39 - -$0.02 | -25.84% | Miss | N/A | 14 | N/A | Apr 29, 2019 | $138.40M |
| Dec 31, 2018 | $0.19 | $0.19 | $0.05 - $0.44 | 0.00% | In line | +171.4% | 15 | N/A | Feb 5, 2019 | $131.45M |
| Sep 30, 2018 | $0.52 | $0.49 | $0.02 - $0.64 | +6.12% | Beat | N/A | 12 | N/A | Nov 5, 2018 | $151.76M |
| Jun 30, 2018 | -$0.07 | -$0.18 | -$0.33 - -$0.12 | +61.11% | Beat | N/A | 9 | N/A | Jul 31, 2018 | $96.91M |
| Mar 31, 2018 | -$0.47 | -$0.30 | -$0.46 - -$0.16 | -56.67% | Miss | N/A | 10 | N/A | Apr 30, 2018 | $71.09M |
| Dec 31, 2017 | $0.07 | $0.18 | -$0.05 - $0.39 | -61.11% | Miss | N/A | 13 | N/A | Feb 13, 2018 | $94.52M |
| Sep 30, 2017 | -$0.13 | -$0.53 | -$0.75 - -$0.15 | +75.47% | Beat | N/A | 12 | N/A | Nov 1, 2017 | $60.77M |
| Jun 30, 2017 | -$0.68 | -$0.65 | -$0.77 - -$0.60 | -4.62% | Miss | N/A | 12 | N/A | Aug 3, 2017 | $6.33M |
| Mar 31, 2017 | -$0.90 | -$0.72 | N/A | -25.00% | Miss | N/A | N/A | N/A | May 9, 2017 | N/A |
| Dec 31, 2016 | -$0.51 | -$0.55 | N/A | +7.27% | Beat | N/A | N/A | N/A | Feb 14, 2017 | $15.00M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.40, up 1.1% from the year before. It was -$1.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.40 | +1.1% |
| Dec 31, 2024 | $6.33 | +65.7% |
| Dec 31, 2023 | $3.82 | +10.4% |
| Dec 31, 2022 | $3.46 | +92.2% |
| Dec 31, 2021 | $1.80 | -56.3% |
| Dec 31, 2020 | $4.12 | +1148.5% |
| Dec 31, 2019 | $0.33 | +94.1% |
| Dec 31, 2018 | $0.17 | N/A |
| Dec 31, 2017 | -$1.64 | N/A |
| Dec 31, 2016 | -$1.62 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,200 words across 31 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,247 | 31 | |
| 2026Q2 | Jun 30, 2026 | 6,932 | 30 | |
| 2026Q1 | Mar 31, 2026 | 7,632 | 29 | |
| 2025Q4 | Dec 31, 2025 | 8,576 | 24 | |
| 2025Q3 | Sep 30, 2025 | 8,154 | 30 | |
| 2025Q2 | Jun 30, 2025 | 8,191 | 29 | |
| 2025Q1 | Mar 31, 2025 | 8,592 | 22 | |
| 2024Q4 | Dec 31, 2024 | 9,820 | 26 |
2026Q3 Earnings Call
Opening remarks
Todd Tushla Vice President of Investor Relations Thank you. And happy Monday, wherever it is that you may be. Welcome to Neurocrine Biosciences Third Quarter 2026 Earnings Call. Joining me on today's call are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Eiry Roberts, Chief Medical Officer; and Samir Siddhanti, Chief Business Officer. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. In addition, some of the information discussed today includes non-GAAP financial measures that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website. Following prepared remarks, we'll be happy to take your questions. With that, I'll hand the call off to Kyle.
Kyle Gano CEO Good afternoon, everyone. Nearly 2 years ago, on my first earnings call as CEO, I shared my optimism about Neurocrine's future and the significant opportunities ahead. Today, that confidence has only grown stronger as I remain deeply confident in our ability to drive sustained growth and create long-term value for our shareholders. Our strategy to build a leading biopharmaceutical company is grounded in execution and delivering meaningful results. In the third quarter, we generated record net product sales of more than $1.1 billion and record profitability. These results underscore the strength of our diversified portfolio of 3 first-in-class medicines and our growing ability to reach and serve more patients than ever before. This momentum positions us well to drive continued growth across INGREZZA, CRENESSITY and VYKAT XR in 2027 and beyond. The strength of our growing commercial business and financial position also enables us to continue investing in our industry-leading pipeline. With several important clinical milestones anticipated in 2027, including Phase III data readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we believe Neurocrine is approaching a potentially transformative period, one that could further expand our pipeline, strengthen our long-term growth prospects and extend our impact on patients. Overall, Neurocrine's third quarter performance exemplifies the strength of our strategy, the discipline of our execution and the significant opportunity ahead to create long-term value. As we close out the year, we look forward to hosting our 2026 R&D Day in New York City on December 15. The event will feature a VYKAT XR panel discussion with Dr.
Frequently Asked Questions About NBIX
When is Neurocrine Biosciences's next earnings date?
Neurocrine Biosciences's next earnings report is expected for Feb 9, 2027.
Did NBIX beat earnings estimates last quarter?
Yes. Neurocrine Biosciences reported EPS of $2.78 for the quarter ended Sep 30, 2026, above the $1.95 estimate, a 42.56% surprise.
What EPS do analysts expect from NBIX next quarter?
The consensus EPS estimate for Neurocrine Biosciences for the quarter ending Dec 31, 2026 is $2.02 from 29 analysts, with estimates from $1.34 to $2.56.
How often does NBIX beat earnings estimates?
Neurocrine Biosciences beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +3.82%.
NBIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors